Tinoco R - Search Results

1

PSGL-1 Immune Checkpoint Inhibition for CD4⁺ T Cell Cancer Immunotherapy.

DeRogatis JM, Viramontes KM, Neubert EN, Tinoco R. DeRogatis JM, et al. Among authors: tinoco r. Front Immunol. 2021 Feb 23;12:636238. doi: 10.3389/fimmu.2021.636238. eCollection 2021. Front Immunol. 2021. PMID: 33708224 Free PMC article. Review.

2

PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion.

Tinoco R, Carrette F, Barraza ML, Otero DC, Magaña J, Bosenberg MW, Swain SL, Bradley LM. Tinoco R, et al. Immunity. 2016 May 17;44(5):1190-203. doi: 10.1016/j.immuni.2016.04.015. Immunity. 2016. PMID: 27192578 Free PMC article.

3

PSGL-1: A New Player in the Immune Checkpoint Landscape.

Tinoco R, Otero DC, Takahashi AA, Bradley LM. Tinoco R, et al. Trends Immunol. 2017 May;38(5):323-335. doi: 10.1016/j.it.2017.02.002. Epub 2017 Mar 2. Trends Immunol. 2017. PMID: 28262471 Free PMC article. Review.

4

PSGL-1 Is a T Cell Intrinsic Inhibitor That Regulates Effector and Memory Differentiation and Responses During Viral Infection.

Tinoco R, Neubert EN, Stairiker CJ, Henriquez ML, Bradley LM. Tinoco R, et al. Front Immunol. 2021 Jul 13;12:677824. doi: 10.3389/fimmu.2021.677824. eCollection 2021. Front Immunol. 2021. PMID: 34326837 Free PMC article.

5

Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1-Resistant Melanoma.

DeRogatis JM, Viramontes KM, Neubert EN, Henriquez ML, Guerrero-Juarez CF, Tinoco R. DeRogatis JM, et al. Among authors: tinoco r. Cancer Immunol Res. 2022 May 3;10(5):612-625. doi: 10.1158/2326-6066.CIR-21-0690. Cancer Immunol Res. 2022. PMID: 35303066 Free PMC article.

6

The cure from within? a review of the microbiome and diet in melanoma.

Kumar P, Brazel D, DeRogatis J, Valerin JBG, Whiteson K, Chow WA, Tinoco R, Moyers JT. Kumar P, et al. Among authors: tinoco r. Cancer Metastasis Rev. 2022 Jun;41(2):261-280. doi: 10.1007/s10555-022-10029-3. Epub 2022 Apr 27. Cancer Metastasis Rev. 2022. PMID: 35474500 Free PMC article. Review.

7

PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells.

Viramontes KM, Neubert EN, DeRogatis JM, Tinoco R. Viramontes KM, et al. Among authors: tinoco r. Front Immunol. 2022 Jun 14;13:869768. doi: 10.3389/fimmu.2022.869768. eCollection 2022. Front Immunol. 2022. PMID: 35774790 Free PMC article.

8

Cell-Intrinsic CD38 Expression Sustains Exhausted CD8⁺ T Cells by Regulating Their Survival and Metabolism during Chronic Viral Infection.

DeRogatis JM, Neubert EN, Viramontes KM, Henriquez ML, Nicholas DA, Tinoco R. DeRogatis JM, et al. Among authors: tinoco r. J Virol. 2023 Apr 27;97(4):e0022523. doi: 10.1128/jvi.00225-23. Epub 2023 Apr 11. J Virol. 2023. PMID: 37039663 Free PMC article.

9

HMGB2 regulates the differentiation and stemness of exhausted CD8⁺ T cells during chronic viral infection and cancer.

Neubert EN, DeRogatis JM, Lewis SA, Viramontes KM, Ortega P, Henriquez ML, Buisson R, Messaoudi I, Tinoco R. Neubert EN, et al. Among authors: tinoco r. Nat Commun. 2023 Sep 13;14(1):5631. doi: 10.1038/s41467-023-41352-0. Nat Commun. 2023. PMID: 37704621 Free PMC article.

10

Regulation of Antigen-Experienced T Cells: Lessons from the Quintessential Memory Marker CD44.

Baaten BJ, Tinoco R, Chen AT, Bradley LM. Baaten BJ, et al. Among authors: tinoco r. Front Immunol. 2012 Feb 27;3:23. doi: 10.3389/fimmu.2012.00023. eCollection 2012. Front Immunol. 2012. PMID: 22566907 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

78 results

Search Page

Filters